The Purpose of This Study is to Compare the Efficacy and Safety of Aficamten (CK-3773274) Compared With Metoprolol Succinate in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Condition: Obstructive Hypertrophic Cardiomyopathy (oHCM) Interventions: Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg); Drug: Placebo to match aficamten; Drug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg); Drug: Placebo to match metoprolol succinate Sponsor: Cytokinetics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 14, 2023 Category: Research Source Type: clinical trials
Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
Conditions: Atrial Fibrillation; Diastolic Dysfunction; HFpEF - Heart Failure With Preserved Ejection Fraction Intervention: Drug: As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil) Sponsor: University of Vermont Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 27, 2023 Category: Research Source Type: clinical trials
